a randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to gnrh analogue therapy in men with non-metastatic castrate-resistant prostate cancer:一项随机,双盲研究比较比卡鲁胺或添加不度他雄胺gnrh类似物治疗男性非转移性阉割性前列腺癌.pdfVIP

a randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to gnrh analogue therapy in men with non-metastatic castrate-resistant prostate cancer:一项随机,双盲研究比较比卡鲁胺或添加不度他雄胺gnrh类似物治疗男性非转移性阉割性前列腺癌.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
a randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to gnrh analogue therapy in men with non-metastatic castrate-resistant prostate cancer:一项随机,双盲研究比较比卡鲁胺或添加不度他雄胺gnrh类似物治疗男性非转移性阉割性前列腺癌

European Journal of Cancer (2015) 51, 1555–1569 A v a i l a b l e a t w w w . s c i e n c e d i r e c t. c o m ScienceDirect journal homepag e: A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate- resistant prostate cancer a,⇑ b c d Franklin M. Chu , Oliver Sartor , Leonard Gomella , Todd Rudo , Matthew C. Somerville e,1, Belinda Hereghty e,1, Michael J. Manyak e a San Bernardino Urological Associates, 489 E. 21 Street, San Bernardino, CA 92404, USA b Medicine and Urology Departments, Tulane School of Medicine, Box SL-42 1430 Tulane Ave, New Orleans, USA c Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19107, USA d GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426, USA e GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, North Carolina, NC 27709, USA Received 27 January 2015; received in revised form 1 April 2015; accepted 28 April 2015 Available online 2 June 2015 KEYWORDS Abstract Background: Bicalutamide blocks androgen action and is frequently used in men Castration-resistant pros- with non-metastatic, castration-resistant prostate cancer (CRPC). By reducing intracellular tate cancer (CRPC) dihydrotestosterone, dutasteride (dual 5-alpha reductase inhibitor) could increase the effec- Dutasteride tiveness of bicalutamide in this setting. The objective of the study is therefore to prospectively

您可能关注的文档

文档评论(0)

ajgoaw + 关注
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档